Akathisia

Akathisia, coined from Ancient Greek a- (ἀ-) 'not' or 'without' and káthisis (κάθισις) 'sitting'. It is a neuropsychiatric syndrome characterized by an intense feeling of inner restlessness accompanied by an irresistible urge to move[1]. Individuals with akathisia often report sensations of tension, anxiety, or discomfort that are relieved temporarily by continuous movement such as pacing, rocking, shifting weight while standing, or repeatedly crossing and uncrossing the legs.

Take heed, this is not the Restless Legs Syndrome[2]. Although commonly associated with antipsychotic medications, akathisia can also occur with antidepressants, antiemetics, and other drugs that affect central nervous system neurotransmitters.

The condition is most frequently observed following the initiation of dopamine-blocking agents, particularly first-generation antipsychotics such as haloperidol. However, second-generation antipsychotics, including risperidone and aripiprazole, may also induce akathisia. Symptoms may emerge within days or weeks of treatment but can occasionally persist for months, resulting in chronic akathisia.

The exact pathophysiology of akathisia remains incompletely understood. Current evidence suggests that blockade of dopamine D₂ receptors, which form complexes (heteromers) with dopamine D₃ and adenosine A₁ receptors, plays a central role. Dopamine is essential for regulating movement and motivation and disruption of dopaminergic signaling may lead to motor restlessness and subjective discomfort.

Additional involvement of other neurotransmitter systems has been proposed, but not scientifically proven, which indicates a complex neurochemical basis.

Clinically, akathisia is significant because it is often misdiagnosed as anxiety, agitation, worsening psychosis, or mood instability. Failure to recognize the disorder can lead to inappropriate treatment adjustments and increased patient distress. Severe akathisia has been associated with poor medication adherence, reduced quality of life, and an elevated risk of suicidal ideation in vulnerable individuals.

Diagnosis is primarily clinical and may be supported by structured assessment tools such as the Barnes Akathisia Rating Scale (BARS). Management typically involves reducing the dose of the offending medication, switching to an alternative one, or administering adjunctive treatments. Beta-blockers, particularly propranolol, are considered among the most effective pharmacological interventions[3]. Benzodiazepines and certain anticholinergic medications may also provide symptomatic relief in some cases.

Early recognition and treatment of akathisia are essential to reduce patient suffering and improve therapeutic outcomes, though this advice seems a bit helpless.

[1] Friedman, Wagner: Akathisia: the syndrome of motor restlessness in American Family Physician - 1987
[2] Ferré et al: Akathisia and Restless Legs Syndrome: Solving the Dopaminergic Paradox in Sleep Medicine Clinics – 2021
[3] Poyurovsky, Weizman: Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT_2a Receptor Antagonists in Drugs - 2020